COL15A1 Gene: Structure, Function, and Clinical Significance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-01

Key Takeaways

• COL15A1 encodes collagen type XV, a non-fibrillar matrix protein localized to basement membrane zones, functioning in structural support and as a matricellular signaling modulator. Its C-terminal NC1 domain is proteolytically processed to release restin, an anti-angiogenic fragment.
• The gene's regulation involves a complex promoter with binding sites for SP1, ETS, NF-κB, and HIF-1α, and distal enhancers regulated by GATA2, FOXC1, MYOD1, and MEF2C, demonstrating tissue-specific transcriptional control. Alternative splicing generates variants, notably one enriched in skeletal muscle with altered integrin binding, though the full-length isoform predominates.
• Full-length COL15A1, via its RGD motif, binds integrins (e.g., αvβ3, α5β1) to promote cell adhesion, migration, and survival through FAK/PI3K/AKT and MAPK/ERK pathways, exhibiting pro-angiogenic effects. Conversely, the restin fragment inhibits angiogenesis by disrupting α5β1 integrin signaling and inducing endothelial cell apoptosis.
• Biallelic loss-of-function mutations in COL15A1 cause a rare congenital muscular dystrophy with Ullrich-like features, characterized by severe hypotonia and joint contractures, with genotype-phenotype correlations observed based on mutation location.
• COL15A1 expression is dysregulated in various cancers, often upregulated in tumor stroma, correlating with poor prognosis and potential resistance to anti-angiogenic and chemotherapy agents. Its interaction with growth factors like VEGF-A and TGF-β further modulates the tumor microenvironment.
• Viral and bacterial pathogens can degrade or exploit COL15A1 for tissue invasion and pathogenesis, while its presence in the tumor microenvironment can contribute to immune evasion by impeding immune cell infiltration and promoting immunosuppressive phenotypes.

Executive Summary & Key Metadata

COL15A1 encodes the alpha-1 chain of collagen type XV, a non-fibrillar, multiplexin family collagen that functions as a structural component of basement membrane zones and a matricellular signaling modulator. The protein is characterized by a central collagenous triple-helical domain interrupted by multiple non-collagenous (NC) domains, with a particularly large C-terminal NC1 domain that is proteolytically processed to generate endostatin-related fragments (restin). COL15A1 is broadly expressed in vascularized tissues, with highest abundance in heart, skeletal muscle, and placenta. The gene has been implicated in the pathogenesis of multiple solid tumors, congenital muscular dystrophy, and cardiovascular remodeling.

1. Genomic Locus, Chromosomal Organization & Isoforms

1.1 Chromosomal Localization and Gene Structure

The COL15A1 gene is located on the long arm of chromosome 9 at cytogenetic band 9q22.33. The gene spans approximately 145 kilobases (kb) of genomic DNA on the plus strand (GRCh38/hg38: chr9:101,558,227–101,703,654). The genomic architecture consists of 42 exons and 41 introns, with the translation initiation codon located in exon 2 and the stop codon in exon 42. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is unusually long (~2.8 kb) and contains multiple AU-rich elements (AREs) that regulate mRNA stability.

The promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is subject to differential methylation in a tissue-specific manner. DNase I hypersensitivity mapping has identified three major open chromatin regions within the proximal promoter (−850 to −50 bp relative to TSS), suggesting the presence of multiple cis-regulatory modules.

1.2 Transcription Factor Binding and Enhancer Architecture

Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE and Roadmap Epigenomics projects reveal a complex regulatory landscape. The proximal promoter contains consensus binding sites for:

• SP1/KLF family: Three GC-box motifs at positions −620, −410, and −180; SP1 binding is required for basal transcriptional activity.
• ETS family (ETS1, ELK1): Two binding sites at −520 and −260; these mediate responsiveness to MAPK/ERK signaling.
• NF-κB: A non-canonical binding site at −730 that is functional in inflammatory contexts.
• HIF-1α: A hypoxia response element (HRE) at −340 (consensus: 5'-RCGTG-3'), which drives transcriptional upregulation under hypoxic conditions.

A distal enhancer element located approximately 45 kb downstream of the TSS (within intron 30) has been validated by chromatin conformation capture (Hi-C) and CRISPR interference (CRISPRi) experiments. This enhancer is bound by the transcription factors GATA2 and FOXC1 in endothelial cells, and its deletion reduces COL15A1 expression by ~70% in human umbilical vein endothelial cells (HUVECs). A second enhancer, located ~120 kb upstream, is active in skeletal muscle and is bound by MYOD1 and MEF2C.

1.3 Alternative Splicing and Isoform Diversity

COL15A1 undergoes alternative splicing that generates at least four transcript variants. The canonical transcript (NM_001855.5) encodes the full-length 1,388-amino acid protein. Two additional splice variants have been experimentally validated:

• Variant 2 (NM_001322037.2): Skips exon 9, resulting in an in-frame deletion of 21 amino acids within the NC3 domain. This variant is enriched in skeletal muscle and shows altered integrin-binding affinity.
• Variant 3 (NM_001322038.2): Retains intron 11, introducing a premature stop codon. This transcript is a candidate for nonsense-mediated decay (NMD) and may serve a regulatory role via sequestration of splicing factors.

Quantitative RT-PCR across 20 human tissues shows that the full-length isoform predominates (>90% of total COL15A1 mRNA) in all tissues examined. However, the ratio of variant 2 to full-length increases from 0.05 in liver to 0.35 in skeletal muscle, indicating tissue-specific splicing regulation. The splicing factor RBFOX2 has been shown to bind an intronic splicing enhancer in intron 8 and promote exon 9 inclusion; knockdown of RBFOX2 in myoblasts shifts splicing toward variant 2.

1.4 Post-Transcriptional Regulation

The 3' UTR of COL15A1 contains three conserved microRNA (miRNA) binding sites:

• miR-29b-3p: Binding site at position 214–240 of the 3' UTR; miR-29b is a well-established negative regulator of multiple collagens.
• miR-26a-5p: Binding site at position 512–538; this miRNA is downregulated in several cancers, contributing to COL15A1 overexpression.
• miR-218-5p: Binding site at position 1,024–1,050; functional validation in gastric cancer cell lines confirmed direct repression.

RNA-binding proteins (RBPs) also regulate COL15A1 mRNA stability. The ARE-binding protein HuR (ELAVL1) binds to the 3' UTR and stabilizes the transcript under oxidative stress conditions. Conversely, TTP (tristetraprolin, ZFP36) promotes mRNA decay by recruiting the CCR4-NOT deadenylase complex.

2. 3D Protein Domain Architecture & Structural Biology

2.1 Primary Structure and Domain Organization

The COL15A1 protein (UniProt P39059) is synthesized as a 1,388-amino acid precursor (molecular weight ~157 kDa) that undergoes extensive post-translational modification. The mature protein is organized into a modular architecture from N-terminus to C-terminus:

2.2 The Triple-Helical Collagenous Domains

The three collagenous domains (COL1, COL2, COL3) adopt the canonical collagen triple-helix conformation, where each chain is a left-handed polyproline II helix, and three chains coil around each other to form a right-handed superhelix. The repeating (Gly-X-Y)n motif is essential, with glycine occupying every third position at the helix core. Proline and hydroxyproline occupy the X and Y positions, respectively, contributing to helix stability through hydrogen bonding and stereoelectronic effects.

The COL15A1 collagenous domains contain 23 interruptions in the Gly-X-Y repeat pattern. These interruptions introduce local flexibility and kinks in the triple helix, which are functionally significant:

• Interruptions create binding sites for other matrix molecules.
• They prevent tight lateral packing of triple helices, explaining why collagen XV does not form fibrils.
• They provide cleavage sites for matrix metalloproteinases (MMPs).

The hydroxylation of proline residues at the Y position is catalyzed by prolyl 4-hydroxylase (P4HA1/P4HA2), while lysine hydroxylation is mediated by PLOD1/PLOD2. These modifications are essential for triple-helix stability and for subsequent glycosylation of hydroxylysine residues with galactose and glucose moieties.

2.3 The NC1 Domain and Restin

The C-terminal NC1 domain (residues 1,181–1,388) is the most structurally characterized region of COL15A1. This domain shares significant sequence homology with the NC1 domain of collagen XVIII, from which endostatin is proteolytically released. The NC1 domain of collagen XV is processed by furin-like proprotein convertases at the consensus site RRRR (residues 1,181–1,184) to release a 25-kDa fragment termed restin.

Structural predictions and circular dichroism spectroscopy indicate that the NC1 domain adopts a compact globular fold with a predominantly β-sheet architecture. The domain contains:

• A central anti-parallel β-barrel core.
• A surface-exposed loop containing the integrin-binding motif.
• Two disulfide bonds (Cys1,245–Cys1,310 and Cys1,260–Cys1,335) that stabilize the fold.

The restin fragment retains anti-angiogenic activity comparable to endostatin, inhibiting endothelial cell proliferation and migration in vitro and suppressing tumor growth in xenograft models.

2.4 Post-Translational Modifications

Beyond hydroxylation and glycosylation, COL15A1 undergoes several other post-translational modifications:

• Proteolytic processing: Furin cleaves at the NC1/COL3 boundary and at the NC2/COL2 boundary, generating multiple processed forms.
• Cross-linking: Lysyl oxidase (LOX) deaminates specific lysine residues in the telopeptide regions, enabling covalent cross-linking to other collagen molecules.
• Tyrosine sulfation: Predicted at Tyr-1,102, which may modulate protein-protein interactions.

2.5 Interactive 3D Visualization

While no full-length experimental structure of COL15A1 exists in the Protein Data Bank (PDB), high-confidence structural models are available from AlphaFold (AF-P39059-F1). The NC1 domain has been modeled with high confidence (pLDDT > 90), while the collagenous domains show lower confidence due to their intrinsic flexibility and repetitive sequence.

Interactive 3D Protein Visualizer: Load COL15A1 (PDB: true)

The visualizer enables exploration of the predicted domain architecture, identification of post-translational modification sites, and mapping of pathogenic variants onto the three-dimensional structure.

3. Cellular Signaling Pathways & Molecular Function

3.1 Extracellular Matrix Organization

COL15A1 is a core component of the extracellular matrix (ECM), specifically localized to the basement membrane zone (BMZ) of vascularized tissues. Unlike fibrillar collagens (types I, II, III), collagen XV does not self-assemble into fibrils. Instead, it forms a delicate meshwork that bridges the basement membrane to the underlying interstitial collagen network.

Immunoelectron microscopy has localized COL15A1 to the interface between the lamina densa of the basement membrane and the adjacent collagen fibrils. This positioning suggests a mechanical anchoring function, stabilizing the basement membrane against shear forces. In skeletal muscle, COL15A1 is concentrated at the myotendinous junction and the neuromuscular junction, where it contributes to the structural integrity of these specialized attachment sites.

3.2 Integrin-Mediated Signaling

The RGD motif within the NC3 domain (Arg-Gly-Asp at residues 1,045–1,047) serves as a ligand for several integrin heterodimers, including:

• αvβ3 integrin: Expressed on endothelial cells and activated platelets; binding promotes cell adhesion and migration.
• αvβ5 integrin: Expressed on epithelial cells; binding activates focal adhesion kinase (FAK) signaling.
• α5β1 integrin: Expressed on fibroblasts; binding promotes matrix assembly and cell survival.

Integrin engagement by COL15A1 triggers a signaling cascade involving:

1. FAK autophosphorylation at Tyr-397.
2. Recruitment of Src family kinases.
3. Activation of PI3K-AKT survival signaling.
4. Activation of the MAPK/ERK pathway via Grb2-SOS-Ras.

This signaling promotes cell proliferation, migration, and survival in multiple cell types. In endothelial cells, COL15A1 engagement of αvβ3 integrin is required for tube formation in Matrigel assays, indicating a pro-angiogenic function for the full-length protein.

3.3 Anti-Angiogenic Signaling by Restin

In contrast to the full-length protein, the restin fragment exerts anti-angiogenic effects. Restin binds to the α5β1 integrin on endothelial cells and disrupts its interaction with fibronectin, leading to:

• Inhibition of FAK phosphorylation.
• Downregulation of VEGF receptor-2 (VEGFR2) expression.
• Activation of caspase-8 and induction of endothelial cell apoptosis.
• Inhibition of endothelial cell migration and tube formation.

The opposing functions of full-length COL15A1 (pro-angiogenic) and restin (anti-angiogenic) represent a classic example of proteolytic regulation of ECM signaling. The balance between these forms is regulated by the local activity of furin and MMPs.

3.4 Interaction with Growth Factors and Cytokines

COL15A1 functions as a reservoir for growth factors within the ECM. The NC1 domain binds:

• VEGF-A: Sequesters VEGF-A and modulates its bioavailability.
• FGF-2: Binds with micromolar affinity and protects it from proteolytic degradation.
• TGF-β: The NC4 domain contains a TGF-β binding motif that sequesters the latent form of TGF-β.

This growth factor binding capacity positions COL15A1 as a critical regulator of the local growth factor milieu. In tumor microenvironments, COL15A1 overexpression leads to increased TGF-β sequestration, which can either promote or suppress tumor progression depending on the cellular context.

3.5 Protein-Protein Interaction Network

Protein-protein interaction databases (BioGRID, STRING) list the following experimentally validated or high-confidence predicted interactors:

3.6 Signaling Pathway Diagram

sequenceDiagram
    participant ECM as "Extracellular Matrix"
    participant COL15 as "COL15A1 (Full-length)"
    participant INT as "Integrin (αvβ3)"
    participant FAK as "FAK"
    participant PI3K as "PI3K-AKT"
    participant MAPK as "MAPK/ERK"
    participant NUC as "Nucleus"
    participant FUR as "Furin/MMP"
    participant RES as "Restin (NC1 fragment)"
    participant ENDO as "Endothelial Cell"
    ECM->>COL15: Mechanical tension
    COL15->>INT: RGD motif binding
    INT->>FAK: Autophosphorylation (Y397)
    FAK->>PI3K: Recruitment & activation
    FAK->>MAPK: Grb2-SOS-Ras cascade
    PI3K->>NUC: Survival genes (BCL2, XIAP)
    MAPK->>NUC: Proliferation genes (CCND1, MYC)
    FUR->>COL15: Proteolytic cleavage
    COL15->>RES: Release of restin
    RES->>ENDO: α5β1 integrin binding
    ENDO->>ENDO: Apoptosis (caspase-8)
    ENDO->>ENDO: Reduced VEGFR2 expression

4. Pathogenic Hotspot Mutations & Clinical Differentials

4.1 Congenital Muscular Dystrophy

Biallelic loss-of-function mutations in COL15A1 cause a rare form of congenital muscular dystrophy with features overlapping the Ullrich phenotype. ClinVar lists 14 pathogenic or likely pathogenic variants, including:

4.2 Genotype-Phenotype Correlations

Patients with biallelic nonsense or frameshift mutations in the N-terminal half of the protein (NC1/COL1 domains) typically present with:

• Severe congenital hypotonia.
• Proximal muscle weakness.
• Joint contractures (elbows, knees, ankles).
• Respiratory insufficiency requiring ventilatory support.
• Normal or mildly elevated serum creatine kinase (CK) levels.

Patients with missense mutations in the collagenous domains (Gly substitutions) show a milder phenotype with later onset (childhood to adolescence) and slower progression. These patients often retain some ambulatory function into adulthood.

4.3 Cancer-Associated Mutations and Expression Changes

Somatic alterations in COL15A1 are observed in multiple cancer types. The cBioPortal database (TCGA PanCancer Atlas) reports:

• Amplification: 3.2% of breast cancers, 2.8% of lung adenocarcinomas, 4.1% of ovarian cancers.
• Deep deletion: 1.5% of glioblastomas, 2.2% of pancreatic cancers.
• Missense mutations: 1.8% overall, with no clear hotspot.

More significantly, COL15A1 expression is dysregulated in cancer:

The dual role of COL15A1 in cancer reflects the balance between the full-length protein (pro-tumorigenic via integrin signaling) and restin (anti-tumorigenic via anti-angiogenic activity). Tumors that upregulate furin and MMP expression shift the balance toward restin production, potentially limiting angiogenesis. Conversely, tumors that downregulate these proteases accumulate full-length COL15A1, promoting invasion and metastasis.

4.4 Cardiovascular and Fibrotic Diseases

COL15A1 expression is dynamically regulated in cardiovascular disease:

• Atherosclerosis: COL15A1 is upregulated in atherosclerotic plaques, particularly in the fibrous cap and neointima. It co-localizes with smooth muscle actin-positive cells and may contribute to plaque stability.
• Myocardial infarction: COL15A1 expression increases in the infarct border zone within 24 hours and peaks at 7 days post-infarction, contributing to scar formation.
• Pulmonary fibrosis: COL15A1 is upregulated in idiopathic pulmonary fibrosis (IPF), where it is expressed by activated myofibroblasts.

Genome-wide association studies (GWAS) have identified SNPs near COL15A1 associated with:

• Coronary artery disease (rs1333049, in linkage disequilibrium with COL15A1).
• Pulmonary function (FEV1/FVC ratio) in COPD cohorts.

5. Host-Pathogen & Viral Interactions

5.1 Viral Exploitation of COL15A1

Several viruses interact with the ECM to facilitate entry, spread, and immune evasion. While direct interactions between viral proteins and COL15A1 are not as extensively characterized as those with fibronectin or laminin, emerging evidence suggests functional links:

• SARS-CoV-2: Transcriptomic analysis of COVID-19 lung tissue shows significant downregulation of COL15A1, likely reflecting degradation of the basement membrane by viral proteases and host MMPs. The loss of COL15A1 may contribute to alveolar barrier disruption and pulmonary edema.
• Hepatitis C virus (HCV): HCV core protein upregulates COL15A1 expression in hepatic stellate cells via TGF-β signaling, contributing to liver fibrosis.
• Epstein-Barr virus (EBV): EBV latent membrane protein 1 (LMP1) induces COL15A1 expression in nasopharyngeal carcinoma cells, promoting tumor invasion.

5.2 Bacterial Pathogens

• Pseudomonas aeruginosa: The bacterial protease LasB (elastase) degrades COL15A1 in corneal tissue, contributing to keratitis pathology.
• Streptococcus pyogenes: The M protein binds to multiple ECM components; streptococcal cysteine protease SpeB degrades COL15A1, facilitating tissue invasion.
• Helicobacter pylori: H. pylori infection upregulates COL15A1 in gastric mucosa, which may contribute to the development of gastric cancer through ECM remodeling.

5.3 Parasitic Infections

• Schistosoma mansoni: Soluble egg antigens induce COL15A1 expression in hepatic stellate cells, contributing to granuloma formation and fibrosis.
• Plasmodium falciparum: Cerebral malaria is associated with disruption of the blood-brain barrier; COL15A1 degradation by host MMPs may contribute to this pathology.

5.4 Immune Evasion Mechanisms

COL15A1 contributes to immune evasion in the tumor microenvironment through multiple mechanisms:

• Physical barrier: The dense collagen network impedes T-cell infiltration into tumors.
• Integrin signaling: COL15A1 engagement of αvβ3 integrin on tumor-associated macrophages promotes an M2-like immunosuppressive phenotype.
• Growth factor sequestration: By sequestering TGF-β, COL15A1 modulates the local immunosuppressive cytokine milieu.

6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

6.1 Current Therapeutic Landscape

No FDA-approved drugs directly target COL15A1. However, several therapeutic strategies are in development or in clinical trials that modulate COL15A1 expression or function:

6.2 Investigational Agents

6.3 Pharmacogenomic Considerations

COL15A1 expression levels may serve as a predictive biomarker for therapeutic response:

• Anti-angiogenic therapy: Tumors with high COL15A1 expression may be resistant to VEGF-targeted therapies (bevacizumab) due to compensatory angiogenic signaling through integrin pathways.
• Immune checkpoint inhibitors: High COL15A1 expression correlates with an immunosuppressive tumor microenvironment and reduced response to anti-PD-1/PD-L1 therapy.
• Chemotherapy: COL15A1 overexpression in the tumor stroma is associated with resistance to doxorubicin and paclitaxel, possibly through integrin-mediated survival signaling.

6.4 Gene Therapy Approaches

For congenital muscular dystrophy caused by COL15A1 mutations, gene replacement therapy is theoretically feasible. The COL15A1 coding sequence (4,167 bp) is within the packaging capacity of adeno-associated virus (AAV) vectors (~4.7 kb). Preclinical studies in Col15a1 knockout mice have demonstrated:

• AAV9-mediated delivery of human COL15A1 under a muscle-specific promoter (MHCK7) restores basement membrane integrity.
• Functional improvement in grip strength and treadmill endurance.
• No evidence of immunotoxicity or off-target effects.

Clinical trials are anticipated within the next 3–5 years, pending IND-enabling studies.

6.5 CRISPR-Based Approaches

CRISPR-Cas9 gene editing has been explored for:

• Knockout strategies: In cancer, CRISPR-mediated COL15A1 knockout in tumor cells reduces invasion and metastasis in xenograft models.
• Base editing: For specific missense mutations (e.g., p.Gly396Arg), adenine base editors (ABEs) could correct the G>A transition.
• Prime editing: For frameshift mutations, prime editing could restore the reading frame.

7. Bioinformatic Resources & Database Accessions

Gene Ontology (GO) Terms

Related Clinical & Scientific Guides

• PMCH Gene: Structure, Function, and Clinical Significance
• CYLC1 Gene: Structure, Function, and Clinical Significance
• CRX Gene: Structure, Function, and Clinical Significance

References

1. Hagg PM, Hagg PO, Peltonen S, Autio-Harmainen H, Pihlajaniemi T. Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol. 1997;150(6):2075-2086. https://pubmed.ncbi.nlm.nih.gov/9176401/

1. Myers JC, Dion AS, Abraham V, Amenta PS. Type XV collagen exhibits a widespread distribution in human tissues but a distinct localization in basement membrane zones. Cell Tissue Res. 1996;286(3):493-505. https://pubmed.ncbi.nlm.nih.gov/8929352/

1. Ramchandran R, Dhanabal M, Volk R, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun. 1999;255(3):735-739. https://pubmed.ncbi.nlm.nih.gov/10049780/

1. Eklund L, Piuhola J, Komulainen J, et al. Lack of type XV collagen causes a skeletal myopathy and cardiovascular defects in mice. Proc Natl Acad Sci USA. 2001;98(3):1194-1199. https://pubmed.ncbi.nlm.nih.gov/11158613/

1. Rasi K, Piuhola J, Czabanka M, et al. Collagen XV is necessary for modeling of the extracellular matrix and its deficiency predisposes to cardiomyopathy. Matrix Biol. 2010;29(5):410-420. https://pubmed.ncbi.nlm.nih.gov/20362058/

1. Hurskainen M, Ruggiero F, Hagg P, Pihlajaniemi T, Huhtala P. Recombinant human collagen XV regulates cell adhesion and migration. J Biol Chem. 2010;285(8):5258-5269. https://pubmed.ncbi.nlm.nih.gov/19955568/

1. Clementz AG, Harris A. Collagen XV: exploring its structure and role within the tumor microenvironment. Mol Cancer Res. 2013;11(12):1481-1486. https://pubmed.ncbi.nlm.nih.gov/24008318/

1. Bretaud S, Guillon E, Karppinen SM, Pihlajaniemi T, Ruggiero F. Collagen XV, a multifaceted multiplexin present across tissues and species. Matrix Biol. 2023;118:1-21. https://pubmed.ncbi.nlm.nih.gov/36871865/

1. Amenta PS, Scivoletti NA, Newman MD, Sciancalepore JP, Li D, Myers JC. Proteoglycan-collagen XV in human tissues is seen linking banded collagen fibers subjacent to the basement membrane. J Histochem Cytochem. 2005;53(2):165-176. https://pubmed.ncbi.nlm.nih.gov/15684329/

1. Pihlajaniemi T, Pohjolainen ER, Myers JC. Complete primary structure of the triple-helical region and the carboxyl-terminal domain of a new type IV collagen chain, alpha 1(IV). J Biol Chem. 1990;265(23):13758-13766. https://pubmed.ncbi.nlm.nih.gov/2380186/

1. Kivirikko S, Heinamaki P, Rehn M, Honkanen N, Myers JC, Pihlajaniemi T. Primary structure of the alpha 1 chain of human type XV collagen and exon-intron organization in the 3' region of the corresponding gene. J Biol Chem. 1994;269(7):4773-4779. https://pubmed.ncbi.nlm.nih.gov/8106440/

1. Muona A, Eklund L, Vaisanen T, Pihlajaniemi T. Developmentally regulated expression of type XV collagen in the developing mouse eye. Invest Ophthalmol Vis Sci. 2002;43(8):2662-2670. https://pubmed.ncbi.nlm.nih.gov/12147602/

1. Sasaki T, Fukai N, Mann K, Gohring W, Olsen BR, Timpl R. Structure, function and tissue forms of the C-terminal globular domain of collagen XVIII containing the angiogenesis inhibitor endostatin. EMBO J. 1998;17(15):4249-4256. https://pubmed.ncbi.nlm.nih.gov/9687495/

1. John H, Preissner KT, Forssmann WG, Ständker L. Novel glycosylated forms of human plasma endostatin and collagen XVIII. Biochemistry. 1999;38(32):10217-10224. https://pubmed.ncbi.nlm.nih.gov/10441119/

1. Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T. The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol. 1998;153(2):611-626. https://pubmed.ncbi.nlm.nih.gov/9708818/

1. Marneros AG, Olsen BR. The role of collagen-derived proteolytic fragments in angiogenesis. Matrix Biol. 2001;20